US China Trade IP Agreement Phase 1-Pharmaceutical related IP issues
US-China Economic and Trade Agreement Phase 1:
What does it mean to US companies and IP attorneys?
Randall Rader, Former Chief Judge of US Federal Circuit of Patent Appeal court
Board of Directors, Trustee, UCIPF
Is China implementing a new linkage system as a result of the Phase 1 Agreement?
How is the new linkage system different from the prior voluntary system?
Jonathan Miao, Senior Partner, NTD Patent & Trademark Agency Limited, China
Has China implemented an orange book type system to identify approved pharmaceuticals which have patent protection?
Is it working to deter Chinese regulatory approval of infringing pharmaceuticals?
Benjamin Hsing, Partner, McguireWoods LLP
The Phase I Agreement does not provide a system of “artificial infringement” for linkage. Can and should China implement a linkage system without “artificial infringement”?
Mark Cohen, Lecturer in Law, Distinguished
Senior Fellow, and Director at the University of California at Berkeley
Member of Advisory Board, UCIPF
Demi Wang, Founder, Chief Executive Officer
Thank you to our supporters!
Demi Wang – Founder, Chief Executive Officer
June 17th, 2020
10 AM – 11:30 AM EST